BlackRock Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

BlackRock Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$54K	Hold	21,319	–	–	﹤0.01%	3239
2016 Q3	$66K	Buy	21,319 +3,501	+20%	+$10.9K	﹤0.01%	3174
2016 Q2	$57K	Buy	17,818 +262	+1%	+$960	﹤0.01%	3198
2016 Q1	$54K	Hold	17,556	–	–	﹤0.01%	3146
2015 Q4	$70K	Sell	17,556 -8,787	-33%	-$40.5K	﹤0.01%	3079
2015 Q3	$121K	Buy	26,343 +1,419	+6%	+$7.43K	﹤0.01%	3007
2015 Q2	$129K	Buy	24,924 +1,573	+7%	+$9.44K	﹤0.01%	3063
2015 Q1	$146K	Buy	23,351 +2,350	+11%	+$13.6K	﹤0.01%	2862
2014 Q4	$132K	Sell	21,001 -771	-4%	-$4.7K	﹤0.01%	2887
2014 Q3	$132K	Sell	21,772 -374	-2%	-$2.55K	﹤0.01%	2854
2014 Q2	$146K	Buy	22,146 +626	+3%	+$7.05K	﹤0.01%	2835
2014 Q1	$512K	Buy	21,520 +1,317	+7%	+$19.1K	﹤0.01%	2029
2013 Q4	$216K	Buy	20,203 +1,611	+9%	+$17.8K	﹤0.01%	2614
2013 Q3	$248K	Sell	18,592 -8	-0%	-$126	﹤0.01%	2407
2013 Q2	$244K	Buy	+18,600	New	+$251K	﹤0.01%	2356

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Advisors's ECYT Position: Q4 2016 in Review

BlackRock Advisors held its Endocyte, Inc. Common Stock (ECYT) position steady in Q4 2016 at 21,319 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #3239.

BlackRock Advisors first reported a position in ECYT in Q2 2013 and has held it in 15 quarters since. The position peaked at $512K in Q1 2014. 96 funds tracked by Wall St. Rank hold ECYT as of Q4 2016.

BlackRock Advisors held 21,319 shares of Endocyte, Inc. Common Stock worth $54K as of Q4 2016.
BlackRock Advisors left its Endocyte, Inc. Common Stock share count unchanged in Q4 2016.
Endocyte, Inc. Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3239 holding.
BlackRock Advisors first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Endocyte, Inc. Common Stock position peaked at $512K in Q1 2014.
96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.